B7-H3 Induces Ovarian Cancer Drugs Resistance Through An PI3K/AKT/BCL-2 Signaling Pathway

References

• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.00627743768
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii61–viii65. doi:10.1093/annonc/mdx44329232466
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Z, Zhang C, et al. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Cancer Sci. 2018;109(9):2697–2705. doi:10.1111/cas.1374430027617
   PubMed Web of Science ®Google Scholar
• Luo L, Zhu G, Xu H, et al. B7-H3 promotes pathogenesis of autoimmune disease and inflammation by regulating the activity of different T cell subsets. PLoS One. 2015;10(6):e0130126. doi:10.1371/journal.pone.013012626065426
   PubMed Web of Science ®Google Scholar
• Ma W, Ma J, Ma P, et al. Targeting immunotherapy for bladder cancer using anti-CD3x B7-H3 bispecific antibody. Cancer Med. 2018;7(10):5167–5177. doi:10.1002/cam4.177530253078
   PubMed Web of Science ®Google Scholar
• Zhou Z, Luther N, G M I, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 2013;111(3):257–264. doi:10.1007/s11060-012-1021-223232807
   PubMed Web of Science ®Google Scholar
• Kreymborg K, Haak S, Murali R, et al. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res. 2015;3(8):849–854. doi:10.1158/2326-6066.CIR-15-010026122284
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-242827208063
   PubMed Web of Science ®Google Scholar
• Lin L, Cao L, Liu Y, et al. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. Leukemia. 2018;33(6):1475–1486.30573782
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574. doi:10.1158/1078-0432.CCR-18-043230655315
   PubMed Web of Science ®Google Scholar
• He L, Li Z. B7-H3 and its role in bone cancers. Pathol Res Pract. 2019;215:152420. doi:10.1016/j.prp.2019.04.01231060912
   PubMed Web of Science ®Google Scholar
• Ma J, Shang T, Ma P, et al. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. Invest New Drugs. 2019;37:1036–1043. doi:10.1007/s10637-018-00719-730706335
   PubMed Web of Science ®Google Scholar
• Han S, Shi X, Liu L, et al. Roles of B7-H3 in cervical cancer and its prognostic value. J Cancer. 2018;9(15):2612–2624. doi:10.7150/jca.2495930087701
   PubMed Web of Science ®Google Scholar
• Zhang F, Li K, Yao X, et al. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311–321. doi:10.1016/j.ebiom.2019.05.00331078520
   PubMed Web of Science ®Google Scholar
• Ling C, Wang X, Zhu J, et al. MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer. Cancer Med. 2019;8:3520–3531. doi:10.1002/cam4.2019.8.issue-731074594
   PubMed Web of Science ®Google Scholar
• Li Y, Guo G, Song J, et al. B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K/Akt/STAT3 signaling pathway. J Cancer. 2017;8(5):816–824. doi:10.7150/jca.1775928382144
   PubMed Web of Science ®Google Scholar
• Yang T, Xu F, Sheng Y, et al. A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer. Anal Bioanal Chem. 2016;408(26):7491–7503. doi:10.1007/s00216-016-9847-727510278
   PubMed Web of Science ®Google Scholar
• P L S, Sasano H, Gao H. Bcl-2 family in non-small cell lung cancer: its prognostic and therapeutic implications. Pathol Int. 2017;67(3):121–130. doi:10.1111/pin.1250728102575
   PubMed Web of Science ®Google Scholar
• Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7(1):65. doi:10.1186/s40425-019-0540-130850021
   PubMed Web of Science ®Google Scholar
• Zhao J, Meng Z, Xie C, et al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2019;108:84–91. doi:10.1016/j.biocel.2019.01.01130664982
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang Z, Li F, et al. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. Oncoimmunology. 2018;7(11):e1461304. doi:10.1080/2162402X.2018.146130430377558
   PubMed Web of Science ®Google Scholar
• Seguin L, Desgrosellier JS, Weis SM, et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234–240. doi:10.1016/j.tcb.2014.12.00625572304
   PubMed Web of Science ®Google Scholar
• Manoochehri Khoshinani H, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy. Cancer Invest. 2016;34(10):536–545. doi:10.1080/07357907.2016.124531727824512
   PubMed Web of Science ®Google Scholar
• Gabellini C, Trisciuoglio D, Del Bufalo D. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain. Carcinogenesis. 2017;38(6):579–587. doi:10.1093/carcin/bgx01628203756
   PubMed Web of Science ®Google Scholar
• Matsushita M, Mori Y, Uchiumi K, et al. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133. FEBS Open Bio. 2019;9(5):935–946. doi:10.1002/feb4.2019.9.issue-5
   PubMed Web of Science ®Google Scholar
• Duan JJ, Cai J, Guo YF, et al. ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int J Cancer. 2016;139(5):965–975. doi:10.1002/ijc.3009126991532
   PubMed Web of Science ®Google Scholar
• Yu TT, Zhang T, Lu X, et al. B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther. 2018;11:4693–4700. doi:10.2147/OTT.S16981130127617
   PubMed Web of Science ®Google Scholar
• Han S, Wang Y, Shi X, et al. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer. Exp Cell Res. 2018;371(1):222–230. doi:10.1016/j.yexcr.2018.08.01430099052
   PubMed Web of Science ®Google Scholar
• Flem-Karlsen K, Fodstad O, Tan M, et al. B7-H3 in cancer – beyond immune regulation. Trends Cancer. 2018;4(6):401–404. doi:10.1016/j.trecan.2018.03.01029860983
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308. doi:10.1038/s41419-019-1549-630952834
   PubMed Web of Science ®Google Scholar
• Janakiram M, Shah UA, Liu W, et al. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev. 2017;276(1):26–39. doi:10.1111/imr.1252128258693
   PubMed Web of Science ®Google Scholar
• Kang FB, Wang L, Jia HC, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45. doi:10.1186/s12935-015-0195-z25908926
   PubMed Web of Science ®Google Scholar